Abstract ISI
JOURNAL OF CLINICAL ONCOLOGY  (2019)

Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

Frontera, OA

Más información

Título según WOS: Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Título de la Revista: JOURNAL OF CLINICAL ONCOLOGY
Volumen: 37
Número: 7
Editorial: LIPPINCOTT WILLIAMS & WILKINS
Fecha de publicación: 2019
Idioma: English
DOI:

10.1200/JCO.2019.37.7_suppl.547
Notas: ISI